

# Complement C4 Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases

Christian Lundtoft,<sup>1</sup> Pascal Pucholt,<sup>1</sup> Myriam Martin,<sup>2</sup> Matteo Bianchi,<sup>3</sup> Emeli Lundström,<sup>4</sup> Maija-Leena Eloranta,<sup>1</sup> Johanna K. Sandling,<sup>1</sup> Christopher Sjöwall,<sup>5</sup> Andreas Jönsen,<sup>6</sup> Iva Gunnarsson,<sup>4</sup> Solbritt Rantapää-Dahlqvist,<sup>7</sup> Anders A. Bengtsson,<sup>6</sup> Dag Leonard,<sup>1</sup> Eva Baecklund,<sup>1</sup> Roland Jonsson,<sup>8</sup> Daniel Hammenfors,<sup>9</sup> Helena Forsblad-d'Elia,<sup>10</sup> Per Eriksson,<sup>5</sup> Thomas Mandl,<sup>2</sup> Sara Magnusson Bucher,<sup>11</sup> Katrine B. Norheim,<sup>12</sup> Svein Joar Auglænd Johnsen,<sup>12</sup> Roald Omdal,<sup>12</sup> Marika Kvarnström,<sup>13</sup> Marie Wahren-Herlenius,<sup>14</sup> Antonella Notarnicola,<sup>4</sup> Helena Andersson,<sup>15</sup> Øyvind Molberg,<sup>15</sup> Louise Pyndt Diederichsen,<sup>16</sup> Jonas Almlöf,<sup>17</sup> Ann-Christine Syvänen,<sup>17</sup> Sergey V. Kozyrev,<sup>3</sup> Kerstin Lindblad-Toh,<sup>18</sup> the DISSECT Consortium, the ImmunoArray Development Consortium, Bo Nilsson,<sup>1</sup> Anna M. Blom,<sup>2</sup> Ingrid E. Lundberg,<sup>4</sup> Gunnel Nordmark,<sup>1</sup> Lina Marcela Diaz-Gallo,<sup>4</sup> Elisabet Svenungsson,<sup>4</sup> and Lars Rönnblom<sup>1</sup>

**Objective.** Copy number variation of the *C4* complement components, *C4A* and *C4B*, has been associated with systemic inflammatory autoimmune diseases. This study was undertaken to investigate whether *C4* copy number variation is connected to the autoimmune repertoire in systemic lupus erythematosus (SLE), primary Sjögren's syndrome (SS), or myositis.

**Methods.** Using targeted DNA sequencing, we determined the copy number and genetic variants of *C4* in 2,290 well-characterized Scandinavian patients with SLE, primary SS, or myositis and 1,251 healthy controls.

**Results.** A prominent relationship was observed between *C4A* copy number and the presence of SSA/SSB autoantibodies, which was shared between the 3 diseases. The strongest association was detected in patients with autoantibodies against both SSA and SSB and 0 *C4A* copies when compared to healthy controls (odds ratio [OR] 18.0 [95% confidence interval (95% CI) 10.2–33.3]), whereas a weaker association was seen in patients without SSA/SSB autoantibodies (OR 3.1 [95% CI 1.7–5.5]). The copy number of *C4* correlated positively with *C4* plasma levels. Further, a common loss-of-function variant in *C4A* leading to reduced plasma *C4* was more prevalent in SLE patients with a low copy number of *C4A*. Functionally, we showed that absence of *C4A* reduced the individuals' capacity to deposit *C4b* on immune complexes.

**Conclusion.** We show that a low *C4A* copy number is more strongly associated with the autoantibody repertoire than with the clinically defined disease entities. These findings may have implications for understanding the etiopathogenic mechanisms of systemic inflammatory autoimmune diseases and for patient stratification when taking the genetic profile into account.

## INTRODUCTION

Systemic inflammatory autoimmune diseases are a group of diseases characterized by inflammation in multiple organs and

the presence of antibodies targeting different ubiquitously expressed cytoplasmic or nuclear proteins. Systemic lupus erythematosus (SLE), primary Sjögren's syndrome (SS), and idiopathic inflammatory myopathies (myositis) are all categorized as

This study was supported by grants from the Swedish Research Council for Medicine and Health, the Swedish Rheumatism Association, King Gustav V's 80-Year Foundation, the Swedish Society of Medicine, the Ingegerd Johansson Donation, the Swedish Heart Lung Foundation, ALF funding from Stockholm County, and KID funding from the Karolinska Institutet. Dr. Lindblad-Toh's work was supported by a Wallenberg Scholarship.

<sup>1</sup>Christian Lundtoft, PhD, Pascal Pucholt, PhD, Maija-Leena Eloranta, PhD, Johanna K. Sandling, PhD, Dag Leonard, MD, PhD, Eva Baecklund, MD, PhD, Bo Nilsson, MD, PhD, Gunnel Nordmark, MD, PhD, Lars Rönnblom, MD, PhD: Uppsala University, Uppsala, Sweden; <sup>2</sup>Myriam Martin, PhD, Thomas Mandl, MD, PhD, Anna M. Blom, PhD: Lund University, Malmö, Sweden;

<sup>3</sup>Matteo Bianchi, PhD, Sergey V. Kozyrev, PhD: Science for Life Laboratory and Uppsala University, Uppsala, Sweden; <sup>4</sup>Emeli Lundström, PhD, Iva Gunnarsson, MD, PhD, Antonella Notarnicola, MD, PhD, Ingrid E. Lundberg, MD, PhD, Lina Marcela Diaz-Gallo, PhD, Elisabet Svenungsson, MD, PhD: Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; <sup>5</sup>Christopher Sjöwall, MD, PhD, Per Eriksson, MD, PhD: Linköping University, Linköping, Sweden; <sup>6</sup>Andreas Jönsen, MD, PhD, Anders A. Bengtsson, MD, PhD: Lund University and Skåne University Hospital, Lund, Sweden; <sup>7</sup>Solbritt Rantapää-Dahlqvist, MD, PhD: Umeå University, Umeå, Sweden; <sup>8</sup>Roland Jonsson, DMD, PhD: University of Bergen, Bergen, Norway; <sup>9</sup>Daniel Hammenfors, MD: Haukeland University Hospital, Bergen, Norway;

systemic inflammatory autoimmune diseases. In SLE, multiple tissues and organs such as the skin, joints, cardiovascular system, and kidneys are commonly affected, whereas a more specific involvement is seen with lacrimal and salivary glands affected in primary SS, and muscle as well as connective tissues in myositis. Despite different patterns of tissue and organ involvement, the 3 diseases share important features, including clinical manifestations, presence of autoantibodies to nuclear antigens, and several genetic loci (1–6).

The complement system plays an important role for clearance of immune complexes and apoptotic cells. Impaired removal of cellular debris may lead to exposure of cellular self-antigens and loss of tolerance (7,8). Although mainly studied in SLE, the complement system has also been shown to play a role in the pathogenesis of primary SS and myositis (9,10). Particularly relevant are the genes in the early classical complement pathway, for which deficiency in any of the genes *C1Q*, *C1R*, *C1S*, *C2*, or *C4* may lead to SLE or lupus-like disease (11). Further, low plasma levels of C3 and C4 are routinely used in the clinical setting as biomarkers for complement activation associated with disease activity and flares in SLE (12,13).

C4 is coded by the paralogous genes *C4A* and *C4B* located between the *HLA* class I and class II regions on chromosome 6. A high level of copy number variation exists for the 2 C4 genes, and while most individuals carry 2 *C4A* copies and 2 *C4B* copies, the number of genes may range from 0 to 5 copies for *C4A* and 0–4 copies for *C4B* (14). By definition, *C4A* and *C4B* differ by 4 amino acids (PCPVLD and LSPVIH, respectively) in exon 26 that also affect the biochemical reactivity toward either amino groups or hydroxyl groups, respectively (15–17).

Previous studies have shown an association between low copy number of *C4A* and systemic inflammatory autoimmune diseases (14,18–20). However, due to the strong linkage disequilibrium (LD) between *C4A* copy number and the extended *C\*07:01–B\*08:01–DRB1\*03:01–DQB1\*02:01* risk haplotype, which is associated with SLE, primary SS, and myositis in populations of European origin, it has been difficult to define whether the association is with *HLA* or with the complement system (21). In a recent study, *C4* copy number rather than *HLA* was suggested to be the main risk factor for SLE (22). This conclusion was based on a parallel analysis of *C4* copy number and *HLA* alleles in

patients of European and African American origin, for which the latter population shows low LD between *C4A* copy number and *DRB1\*03:01*.

Due to a high homology between the genomic reference sequences of *C4A* and *C4B* (99.91% identical), the 2 genes are generally excluded from variant calling analysis due to ambiguous mapping of sequencing reads. In addition, a diploid state is assumed in variant calling of human autosomes, which is incompatible with the high level of variation in the *C4* copy number ranging from 2 to 8 *C4* copies. Therefore, variation in *C4* genes at nucleotide level and the association to disease remain relatively unexplored.

The purpose of the current study was to perform a focused analysis of *C4* copy number and *C4* nucleotide variation in patients with 3 systemic inflammatory autoimmune diseases and in healthy controls. In parallel, we aimed to evaluate the relation between *HLA* alleles and *C4* copy number variation, for which the combined analysis of 3 cohorts of patients with SLE, primary SS, or myositis allowed the comparison of shared and distinct patterns within and between the diseases.

## PATIENTS AND METHODS

**Study participants.** Patients diagnosed as having SLE, primary SS, or myositis at Scandinavian rheumatology clinics, as well as healthy blood donors/population controls have been previously described in detail (23–25), and basic characteristics are presented in Supplementary Table 1, available on the *Arthritis & Rheumatology* website at <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>. For validation of *C4* copy number calls and *HLA* alleles, we included whole-genome sequencing data from 75 parent/offspring trios, in which offspring were diagnosed as having SLE (26). The individual studies were approved by local ethics committees, and all study participants provided written informed consent.

**Targeted sequencing, genotyping, and quality control.** The capturing array and the targeted DNA sequencing of patients and healthy controls has previously been described (23–25,27). A detailed description of the sequencing workflow, alignment, genotype calling, and quality control at variant- and individual-based levels can be found in the Supplementary

<sup>10</sup>Helena Forsblad-d'Elia, MD, PhD: Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; <sup>11</sup>Sara Magnusson Bucher, MD: Örebro University, Örebro, Sweden; <sup>12</sup>Katrine B. Norheim, MD, PhD, Svein Joar Auglænd Johnsen, MD, PhD, Roald Omdal, MD, PhD: Stavanger University Hospital, Stavanger, Norway; <sup>13</sup>Marika Kvarnström, MD, PhD: Karolinska Institutet, Karolinska University Hospital, and Stockholm Health Services, Region Stockholm, Stockholm, Sweden; <sup>14</sup>Marie Wahren-Herlenius, MD, PhD: Karolinska Institutet and Karolinska University Hospital Stockholm, Sweden, and University of Bergen, Bergen, Norway; <sup>15</sup>Helena Andersson, MD, PhD, Øyvind Molberg, MD, PhD: Oslo University Hospital, Oslo, Norway; <sup>16</sup>Louise Pyndt Diederichsen, MD, PhD: Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, and Odense University Hospital, Odense, Denmark;

<sup>17</sup>Jonas Almlöf, PhD, Ann-Christine Syvänen, PhD: Science for Life Laboratory and Uppsala University, Uppsala, Sweden; <sup>18</sup>Kerstin Lindblad-Toh, PhD: Science for Life Laboratory and Uppsala University, Uppsala, Sweden, and Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Author disclosures are available at <https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42122&file=art42122-sup-0001-Disclosureform.pdf>.

Address correspondence to Lars Rönnblom, MD, PhD, Department of Medical Sciences, Rheumatology, Rudbeck Laboratory, Dag Hammarskjölds Väg 20, Uppsala University, 75185 Uppsala, Sweden. Email: [lars.ronnblom@medsci.uu.se](mailto:lars.ronnblom@medsci.uu.se).

Submitted for publication September 21, 2021; accepted in revised form March 15, 2022.

Information, available on the *Arthritis & Rheumatology* website at <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>.

DNA sequencing and genotyping was performed at the SNP&SEQ Technology Platform in Uppsala, part of the National Genomics Infrastructure Sweden and Science for Life Laboratory. The computations were enabled by resources in projects sens2017142 and sens2020577, provided by the Swedish National Infrastructure for Computing at Uppsala Multidisciplinary Center for Advanced Computational Science.

**Estimation of *C4* copy number and calling of *HLA* alleles from targeted sequencing data.** The total copy number of *C4* was estimated based on read depth using the GermlineCNVCaller (GATK), and the relative read depths of 5 *C4A/C4B*-specific single-nucleotide variants were used for ascertainment of total number of *C4* copies into copy number of *C4A* and *C4B*. Genetic variants in the *C4A/C4B* genes were called at bp resolution using the HaplotypeCaller (GATK). The human endogenous retrovirus element present in some *C4* genes (28) was not analyzed (Supplementary Information, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>).

*HLA* alleles of 6 *HLA* genes (*HLA-A*, *HLA-B*, *HLA-C*, *HLA-DPB1*, *HLA-DQB1*, and *HLA-DRB1*) were called at 4-digit resolution from sequencing data using xHLA (29). A detailed workflow for the analysis of *C4* and *HLA* is available in the Supplementary Information together with method validation using results from previous polymerase chain reaction-based *C4* analyses (30–32).

**Plasma *C4* concentration and autoantibody status of patients.** Measurement of plasma *C4* in SLE and primary SS patients was performed at local centers as part of clinical routine (33,34). Information about autoantibodies was extracted from medical records, and healthy controls were included as a reference cohort under the assumption that autoantibodies are specific to patients. Nevertheless, a small percentage of the individuals in the general population may be positive for autoantibodies (34), but the impact on this study is considered negligible.

***C4b* deposition on heat-aggregated human IgG.** Serum from healthy individuals carrying only *C4A* genes or only *C4B* genes were incubated with heat-aggregated IgG, and deposition of *C4b* was detected by enzyme-linked immunosorbent assay, as described in the Supplementary Information (<https://onlinelibrary.wiley.com/doi/10.1002/art.42122>).

**Statistical analysis.** Statistical analyses were performed in R version 4.0.4 (35). Two-tailed *P* values less than 0.05 were considered significant. The statistical tests and covariates that were included (e.g., principal components for genetic population structure) are described in the text and figure legends. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. For analysis of associations in the *HLA* region, a Bonferroni

correction for 5,000 tests was used, corresponding to a statistical significance threshold of  $1 \times 10^{-5}$ .


**Data availability.** Raw data for individual figures are available in the Supplementary Information (<https://onlinelibrary.wiley.com/doi/10.1002/art.42122>). Genotype data at the individual level are not publicly available since they contain information that could compromise research participant privacy and consent. Scripts for calling *C4* copy number in GermlineCNVCaller are available upon request. Members of the DISSECT consortium and the ImmunoArray consortium are described in the Supplementary Appendix (<https://onlinelibrary.wiley.com/doi/10.1002/art.42122>).

## RESULTS

**Association of *C4A* copy number with systemic inflammatory autoimmune diseases.** Using targeted sequencing data, we estimated the *C4* copy number in 2,290 patients diagnosed as having SLE, primary SS, or myositis, and in 1,251 healthy controls (Figure 1A). The total *C4* copy number calls ranged from 2 to 8 *C4* copies, but since only 2 individuals had more than 6 *C4* copies (Supplementary Information, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>), we focused on subjects with 2–6 *C4* copies.

Notably, the pattern in *C4* copy number was relatively similar among the 3 systemic inflammatory autoimmune diseases, and therefore, we performed both joint and separate analyses of the diseases. As previously observed, a low *C4* copy number was associated with an increased risk of all 3 diseases compared to healthy controls (*P* for *C4* =  $2 \times 10^{-38}$ ) (Figure 1B and Supplementary Figure 1A, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>), and this association was almost exclusively explained by the copy number of the *C4A* gene (*P* for *C4A* =  $5 \times 10^{-45}$ ) (Figure 1C). We noted a negative correlation between *C4A* copy number and *C4B* copy number ( $r_s = -0.50$ ) (Supplementary Figure 1B), and although the copy number of *C4B* was slightly higher in patients compared to controls, each decrease in *C4B* copy number was modestly associated with an increased risk of systemic inflammatory autoimmune disease when adjusting for the effect of *C4A* (*P* for *C4B* =  $6 \times 10^{-4}$ ) (Figure 1C and Supplementary Figure 1A). Based on these results, we concluded that low *C4A* copy number is a strong risk factor for systemic inflammatory autoimmune disease, whereas the effect of *C4B* is limited.

**Overlap of association with autoantibodies against SSA and SSB between systemic inflammatory autoimmune diseases.** Autoantibodies against nuclear antigens are a common feature and part of the clinical evaluation of SLE, primary SS, and myositis, and therefore, we analyzed whether *C4A* copy number was associated with the autoantibody repertoire in patients. A strong and consistent association was detected



**Figure 1.** Association between complement *C4* copy number and 3 systemic inflammatory autoimmune diseases (SIADs). **A** Workflow for analysis. Three patient groups with systemic inflammatory autoimmune diseases and 1 reference cohort were analyzed for *HLA* alleles and copy number of the paralogous *C4* genes *C4A* and *C4B*, using targeted sequencing data. Association analysis of *C4* was performed for clinical subsets of the diseases. Additionally, common and rare variants in the *C4* genes were analyzed from the sequencing data. **B**, Total *C4* copy number in healthy controls and patients with systemic lupus erythematosus (SLE), primary Sjögren's syndrome (SS), or myositis ( $n = 3,541$ ). Logistic regression was performed to analyze associations in the combined patient group compared to healthy controls, with adjustment for sex and principal components 1–4 (PC1–PC4). Odds ratios (ORs) represent disease risk in association with each decrease in *C4* copy number. **C**, Copy number of *C4A* and *C4B* in each patient group and healthy controls ( $n = 3,520$ ). Analysis is based on logistic regression with both *C4A* and *C4B* included as additive variables and with adjustment for sex and PC1–PC4. ORs represent disease risk in association with each decrease in *C4A* or *C4B* copy number. MHC = major histocompatibility complex; CI<sub>95%</sub> = 95% confidence interval.

between low *C4A* copy number and presence of anti-SSA and anti-SSB autoantibodies in all 3 diseases (Supplementary Table 2, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>). None of the other autoantibodies investigated for all diseases were consistently associated with *C4A* copy number (Supplementary Table 2).


The prevalence of anti-SSA/SSB autoantibodies differed highly among the diseases and was highest in primary SS, with 73% of patients having autoantibodies against SSA and/or SSB (Figure 2A). For myositis, 32% of patients had anti-SSA/SSB autoantibodies with most being against SSA and only 2.4% of patients being positive for both anti-SSA and anti-SSB. In SLE, 41% of patients had autoantibodies against SSA and/or SSB. A few patients (2.4%) had autoantibodies against SSB only, which is in line with the notion that anti-SSA antibodies appear first and may be followed by anti-SSB antibodies due to epitope spreading (36).

Remarkably, we observed a dose–response relationship between *C4A* copy number and the prevalence of autoantibodies against SSA and SSB in all 3 diseases. Each decrease in *C4A* copy number was associated with an increased risk of autoantibodies against both SSA and SSB (OR 5.89 [95% CI 4.83–7.23]), whereas the association with the systemic inflammatory autoimmune diseases without any autoantibodies against SSA/SSB was more modest (OR 1.53 [95% CI 1.36–1.73])

(Figure 2B). Patients with autoantibodies against either SSA or SSB showed a similar intermediate association, and therefore, we combined anti-SSA+SSB– and anti-SSA–SSB+ patients into 1 group (OR 2.37 [95% CI 2.02–2.77]).

Despite slight differences between the diseases, the associations of *C4A* copy number were more specific to the presence of anti-SSA/SSB autoantibodies than to the individual diseases, and thus, we evaluated the prevalence of autoantibodies against number of *C4A* copies collectively for the 3 diseases. This revealed a strong effect of *C4A* copy number on the association with autoantibodies against SSA/SSB, in which the risk of disease with anti-SSA/SSB autoantibodies for individuals with a *C4A* copy number of 0 was ~80 times higher than for individuals with a *C4A* copy number of 3 (Figure 2C). Interestingly, each change in *C4A* copy number was associated with a consistent change in disease risk.

In addition to a genetic association between *C4* copy number and autoantibodies against SSA and SSB, we also identified a functional association linking the two parameters. As previously shown (22,37), plasma C4 levels in patients with primary SS showed higher concentrations with an increasing copy number of *C4A* and *C4B* (Figure 2D). Additionally, we detected lower plasma C4 levels in patients with



**Figure 2.** Association between *C4* copy number and anti-SSA/SSB autoantibodies. **A**, Prevalence of anti-SSA/anti-SSB autoantibodies in patients with SLE ( $n = 919$ ), primary SS ( $n = 902$ ), or myositis ( $n = 364$ ). **B**, Logistic regression analysis of association between each decrease in *C4A* copy number and anti-SSA/anti-SSB autoantibody status among each patient group compared to healthy controls. Dotted lines indicate ORs for association in the combined group of 3 diseases. **C**, Logistic regression analysis of association between *C4A* copy number and anti-SSA/anti-SSB autoantibody status in the combined patient group compared to healthy controls. In **B** and **C**, bars represent 95% confidence intervals, and models have been adjusted for presence of *C4B*, sex, and PC1–PC4. **D**, Plasma *C4* levels in patients with primary SS. Groups were compared by analysis of variance with square root–transformed values for the *C4* concentration, adjusted for sex and cohort ( $n = 470$ ). *C4A* and *C4B* copy number was included in the model; the x-axis shows total *C4* copy number for simplicity. **E**, Deposition of the complement activation product *C4b* on heat-aggregated human IgG, analyzed with varying concentrations of serum from healthy individuals carrying *C4A* genes only ( $n = 5$ ) or *C4B* genes only ( $n = 5$ ). The samples were analyzed  $\geq 3$  times, and the mean absorbance for each sample was evaluated using the Mann-Whitney U test. In **D** and **E**, Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median, and whiskers extend to 1.5 times the interquartile range. See Figure 1 for other definitions. Color figure can be viewed in the online issue, which is available at <http://onlinelibrary.wiley.com/doi/10.1002/art.42122/abstract>.

primary SS with autoantibodies against SSA/SSB when compared to patients with primary SS without anti-SSA/SSB autoantibodies (Figure 2D), suggesting a direct connection between anti-SSA/SSB autoantibodies and plasma *C4*. However, a similar association between plasma *C4* and anti-SSA/SSB was not found for SLE patients ( $P = 0.41$ ;  $n = 411$ ) (Supplementary Figure 2A, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>).

By analyzing serum from healthy individuals carrying *C4A* genes only or *C4B* genes only, we detected a higher deposition of the *C4* activation product *C4b* on aggregated human IgG for *C4A* carriers (Figure 2E). These results are consistent with the proposed role of *C4A* being more efficient than *C4B* in clearance of immune complexes and suggest a connection between low *C4A* copy number and impaired removal of immune complexes in systemic inflammatory autoimmune disease.

In summary, we showed a strong association between *C4A* copy number and autoantibodies against SSA and SSB, which to a greater extent represented an association with anti-SSA/SSB autoantibodies rather than with the systemic inflammatory autoimmune diseases themselves.

**Higher proportion of SLE patients carrying the *C4A* loss-of-function (LoF) variant rs760602547.** We continued by evaluating a common LoF variant (rs760602547) mainly found in *C4A*. The LoF variant results in a CT insertion in exon 29, which introduces a premature stop codon in *C4A* (38).

We called the LoF variant rs760602547 for patients and controls and detected the CT insertion in 7.7% of all individuals. Among the LoF carriers, 98% had 1 LoF variant, and the variant was not found among any of those carrying only *C4B* genes, thus supporting the notion that the CT insertion mainly is found in *C4A* and rarely in *C4B* (39). When analyzing the number of LoF variants in patients with SLE, primary SS, or myositis compared to healthy controls, no enrichment of the variant was seen in patients ( $P > 0.10$  by logistic regression). However, logistic regression analysis allowing for interaction between *C4A* copy number and the LoF variant rs760602547 showed that SLE patients with a low *C4A* copy number carried the LoF variant to a greater extent than controls ( $P$  for LoF = 0.01;  $P$  for interaction = 0.03 [ $n = 2,136$ ]) (Figure 3A), indicating an additional mechanism of impaired *C4A* function in SLE. The increased frequency of the LoF variant among SLE patients with a low *C4A* copy number

was also seen in a focused analysis of SLE patients and healthy controls with 1–2 *C4A* copies ( $P = 0.01$  by Fisher’s exact test;  $n = 1,559$ ). For patients with primary SS and those with myositis, no association was found for the LoF variant ( $P$  for interaction  $> 0.10$ ) (Figure 3A). Grouping patients based on anti-SSA/SSB autoantibody status showed a tendency toward an increased frequency of the LoF variant in SSA/SSB-negative patients when compared to healthy controls, whereas no association was seen for the patients with SSA/SSB autoantibodies (Figure 3B).


Analysis of plasma C4 by linear regression showed lower C4 concentrations for carriers of the LoF variant rs760602547 (SLE:  $P = 8 \times 10^{-5}$  [ $n = 407$ ]; primary SS:  $P = 5 \times 10^{-4}$  [ $n = 471$ ]) (Supplementary Figure 3A, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>) after accounting for the copy number of *C4A* and *C4B*, demonstrating that the LoF variant directly affects plasma C4 concentration.

To ensure that the enrichment of the LoF variant rs760602547 in SLE patients with a low *C4A* copy number was not caused by an indirect linkage to *DRB1\*03:01* or other SLE-associated *HLA* alleles, we analyzed the LD between the LoF

variant and common variants in *C4*, *HLA* alleles, and single-nucleotide polymorphisms (SNPs) in the *HLA* region. We detected multiple SNPs and *C4* variants in high LD with the LoF variant (Supplementary Figure 3B, Supplementary Data). For *HLA* alleles, the strongest LD was seen with *DQB1\*06:04* ( $R^2 = 0.56$ ), whereas *C4* copy number or *DRB1\*03:01* was not in LD with the LoF variant rs760602547 ( $R^2 < 0.10$ ). Therefore, the association of the LoF variant was independent of SLE-associated *HLA* alleles.

Overall, we detected lower plasma C4 levels in carriers of the LoF variant rs760602547, and the LoF variant was enriched in SLE patients with a low *C4A* copy number, thereby adding another level of complexity in the genetic variation of the complement system.

**No enrichment of rare *C4* variants in systemic inflammatory autoimmune diseases.** Due to the common variation in *C4* copy number, together with the high sequence homology between *C4A* and *C4B* (99.91% identical), nucleotide variants in the *C4* genes are generally omitted from sequencing-based analyses. By using information about the *C4* copy number for each individual while analyzing *C4* nucleotide variants



**Figure 3.** Loss-of-function (LoF) variant in *C4A* and rare variants in *C4* genes. **A**, Proportion of patients and healthy controls carrying the *C4A* LoF variant rs760602547. **B**, Proportion of the LoF variant rs760602547 among SSA/SSB autoantibody subgroups combined across the 3 systemic inflammatory autoimmune diseases and healthy controls. Patients (or SSA/SSB subgroups) and controls were grouped based on *C4A* copy number, and the size of points indicate the total number of individuals in each group with the specific *C4A* copy number.  $P$  values are based on logistic regression with interaction between *C4A* copy number and rs760602547. The LoF variant was only present among individuals with 1–4 *C4A* genes. **C**, Number of individuals carrying rare (present among  $< 0.5\%$  of all individuals) coding variants in  $\geq 1$  *C4* gene (synonymous,  $n = 44$ ; missense,  $n = 100$ ). Variants present among 10–17 individuals have been combined. **D**, Number of *C4* genes carrying a rare coding variant in each disease cohort. The number of variants in each disease group has been adjusted for total *C4* copy number in order to account for lower copy number of *C4* among patients with systemic inflammatory autoimmune diseases. See Figure 1 for other definitions. Color figure can be viewed in the online issue, which is available at <http://onlinelibrary.wiley.com/doi/10.1002/art.42122/abstract>.


(Supplementary Information, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>), we called common and rare variants for all study participants, focusing on coding variants. As variants could not be assigned unambiguously to *C4A* or *C4B*, variants were analyzed relative to the total *C4* copy number.

Overall, we detected 144 rare coding variants (present among <0.5% of all study participants). Of these variants, 65% were found in only 1 individual, and 69% of the variants were missense variants (Figure 3C and Supplementary Information). Analysis of rare coding variants in each disease group did not indicate an enrichment of rare synonymous or missense variants in any of the systemic inflammatory autoimmune diseases (Figure 3D). Further, prediction of the effect of missense variants did not show an enrichment of putative benign or deleterious variants in systemic inflammatory autoimmune diseases (Supplementary Figure 3C, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>), and no difference

was detected for rare *C4* variants in patients grouped based on anti-SSA/SSB autoantibody status (Supplementary Figure 3D).

In summary, we detected 144 rare variants in the coding sequence of *C4*, but no enrichment was observed in *C4* genes of patients with systemic inflammatory autoimmune disease.

**Anti-SSA/SSB autoantibody subgroups and association with *HLA* and *C4*.** Although the association of *C4A* copy number was more specific to anti-SSA/SSB autoantibody status than to the individual disease entity (Figure 2B), we noted some differences between the 3 systemic inflammatory autoimmune diseases. The most striking difference was observed for patients without anti-SSA/SSB autoantibodies, in which no association was seen between *C4A* copy number and primary SS (OR 1.13,  $P = 0.23$ ), while a strong association was seen for a decrease in *C4A* copy number among myositis patients



**Figure 4.** Association of variants in the *HLA* region with anti-SSA/SSB-negative and anti-SSA/SSB-positive patients. **A**, Association of variants in *HLA* region in patients with SLE ( $n = 544$ ), primary SS ( $n = 241$ ), or myositis ( $n = 247$ ) who were negative for autoantibodies against SSA/SSB, as compared to healthy controls ( $n = 1,251$ ). **B**, Regional association plot of *HLA* variants in patients with SLE ( $n = 168$ ) or primary SS ( $n = 368$ ) who were positive for autoantibodies against both SSA and SSB, as compared to healthy controls ( $n = 1,251$ ). Few myositis patients ( $n = 11$ ) had autoantibodies to both SSA and SSB, and therefore the data for these patients were not plotted. *HLA* alleles for 6 genes (*HLA-A*, *HLA-C*, *HLA-B*, *HLA-DRB1*, *HLA-DQB1*, and *HLA-DPB1*) and variants in *C4* present in >1% of individuals were included in the analysis. Groups were analyzed for associations using logistic regression with adjustment for sex and PC1–PC4. Dashed lines represent the Bonferroni-corrected significance threshold ( $P = 1 \times 10^{-5}$ ). Color figure can be viewed in the online issue, which is available at <http://onlinelibrary.wiley.com/doi/10.1002/art.42122/abstract>.

(OR 1.91,  $P = 4 \times 10^{-11}$ ) and to a lesser extent among SLE patients (OR 1.55,  $P = 2 \times 10^{-8}$ ) (Figure 2B).

In order to evaluate whether other variants in the *HLA* region could explain these differences, we analyzed the association of SNPs, *HLA* alleles, *C4* copy number, and common variants in the *C4* genes in relation to the autoantibody status for each of the individual diseases. Global analysis of the *HLA* region generally showed an association with the extended *C\*07:01–B\*08:01–DRB1\*03:01–DQB1\*02:01* haplotype together with *C4A* copy number in both SLE and myositis patients without anti-SSA/SSB autoantibodies (Figure 4A). No additional associations were present after conditioning for the *HLA* allele with the strongest association (Supplementary Figure 4, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>). For patients with primary SS without autoantibodies to SSA/SSB, no association was seen with the *HLA* region (Figure 4A), suggesting at least partially different autoimmune processes among the 3 systemic inflammatory autoimmune diseases for the anti-SSA/SSB-negative subset of patients.

We continued analyzing genetic variation in the *HLA* region for patients with autoantibodies against both SSA and SSB. Due to the low number of anti-SSA/SSB-positive myositis patients ( $n = 11$ ), we focused on SLE and primary SS patients. Again, the extended *C\*07:01–B\*08:01–DRB1\*03:01–DQB1\*02:01* haplotype together with *C4A* copy number generally showed a strong association with SLE and primary SS patients with autoantibodies against both SSA and SSB (Figure 4B). After conditioning for *DQB1\*02:01* and *C4A* copy number, no additional association with *HLA* alleles was found for SLE (Supplementary Figure 5A, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>), whereas conditional analysis showed an association with *DRB1\*03:01*, *DRB1\*15:01*, *DQB1\*04:02*, and *B\*08:01* in anti-SSA/SSB-positive patients with primary SS patients (Supplementary Figure 5B).

The genomic reference sequence for *C4A* and *C4B* differs at 18 nucleotide positions of which 5 variants in exon 26 are used for defining copy number of *C4A* and *C4B* (Supplementary Information). In addition to the variants differing between *C4A/C4B* reference sequences, we detected 78 variants found in  $\geq 1$  *C4A/C4B* gene among more than 1% of the individuals. We included all 96 common variants in the analysis of the *HLA* region, using the number of *C4* genes, with alternative alleles for each variant as variables in the analysis. However, the copy number of *C4A* generally explained the largest part of the associations with minimal effect of individual variants in the *C4* genes (Figure 4 and Supplementary Figure 5).

In addition to the analysis of anti-SSA/SSB-negative and anti-SSA/SSB-positive patients against healthy controls, we also performed a pairwise case–case analysis of autoantibody subsets within the individual diseases and for the 3 systemic inflammatory autoimmune diseases combined. Again, the extended *C\*07:01–B\*08:01–DRB1\*03:01–DQB1\*02:01* haplotype together with *C4A* copy number explained the main association (Supplementary Figure 6, <https://onlinelibrary.wiley.com/doi/10.1002/art.42122>).

In summary, no association was seen between the *HLA* region and primary SS patients without any autoantibodies against SSA and SSB, in contrast with anti-SSA/SSB-negative SLE and myositis patients. Further, the extended *C\*07:01–B\*08:01–DRB1\*03:01–DQB1\*02:01* haplotype together with *C4A* copy number was associated with both anti-SSA/SSB-positive systemic inflammatory autoimmune diseases as well as SLE and myositis without anti-SSA/SSB autoantibodies. In conditional analyses, *C4A* copy number generally followed the extended *HLA* haplotype, and the copy number of *C4A* largely explained the association with *C4* with a minor effect of individual variants in the *C4* genes.

## DISCUSSION

In the current study, we demonstrated a strong association between low *C4A* copy number and the presence of anti-SSA/SSB autoantibodies in the 3 systemic inflammatory autoimmune diseases: SLE, primary SS, and myositis. The similarities between the disease associations indicated that a low *C4A* copy number to a higher extent is associated with anti-SSA/SSB autoantibodies rather than to the individual disease entities.

Autoantibodies, such as anti-SSA and anti-SSB, generally appear several years before clinical onset of both SLE (40,41) and primary SS (42,43), indicating a slow progression from asymptomatic autoimmunity to clinical manifestations. Here, we demonstrated that a genetic susceptibility with a low *C4A* copy number is a risk factor for development of anti-SSA/SSB autoantibodies, and when present, the autoantibodies may contribute to systemic inflammatory autoimmune disease in a subset of individuals. Moreover, these observations may explain the partial overlap in clinical manifestations between diseases for a subgroup of patients (e.g., in SLE, in which 25% of patients are affected by secondary SS [44]). However, the low number of myositis patients with autoantibodies against both SSA and SSB limits the conclusions that can be drawn from this subset of patients.

Although the *C4A* copy number was associated with anti-SSA/SSB autoantibodies in a dose-dependent manner, the association between *C4A* copy number and systemic inflammatory autoimmune diseases without anti-SSA/SSB autoantibodies was limited. As described previously, no association with the *HLA* region was found for anti-SSA/SSB-negative patients with primary SS (24,45). In contrast, *C4A* copy number together with the extended *C\*07:01–B\*08:01–DRB1\*03:01–DQB1\*02:01* haplotype showed a residual association with anti-SSA/SSB-negative patients with SLE and myositis, which is consistent with earlier reports indicating *DRB1\*03:01* as a risk factor in SLE patients without anti-SSA/SSB autoantibodies (46,47). This suggests partly different etiopathogenetic mechanisms for anti-SSA/SSB-negative patients with primary SS compared to patients with SLE or myositis.



We note that the Scandinavian study population in the current analysis is relatively homogenous, which may limit the generalizability of the study. Still, the variation in *C4* copy numbers generally follows the pattern reported in other studies of individuals of European ancestry (14,18,22).

While it is difficult to distinguish the association signal from *C4A* copy number and *DRB1\*03:01* in populations of European descent, several lines of evidence support the notion that *C4A* copy number plays a central role in systemic inflammatory autoimmune diseases. Analysis of *C4* copy number in SLE patients of East Asian (48) and African American origin (22)—populations in which the LD between *C4A* copy number and *DRB1\*03:01* is low—showed a strong risk with a low *C4* copy number. The importance of the complement system is further supported by the strong risk of SLE and lupus-like symptoms often including anti-SSA autoantibodies in individuals with deficiencies in any of the early classical complement pathway genes *C1Q*, *C1R*, *C1S*, *C4*, and *C2* (10,11).

The higher frequency of the common deleterious *C4A* variant among SLE patients with a low *C4A* copy number adds an additional modulating factor to the variation in *C4A* copy number and plasma levels of *C4* among SLE patients. Previous analyses of the LoF variant did not detect any enrichment in SLE patients (21,49). However, a larger cohort, along with a slightly increased frequency of the LoF variant, may explain the enrichment detected in the current study. Further, the enrichment was only seen when taking the *C4A* copy number into account, which was not done in the previous studies. Nevertheless, no enrichment of the LoF variant was seen in patients with primary SS or myositis, suggesting a higher vulnerability among SLE patients.

Despite a high similarity between the *C4A* and *C4B* proteins, a low copy number of *C4A* explained the major risk for systemic inflammatory autoimmune disease with only a minor effect for the *C4B* copy number. The 4 *C4A/C4B*-defining amino acids in exon 26 of *C4* alter the reactivity of *C4A* and *C4B* toward amino groups and hydroxyl groups, respectively. This is thought to increase the efficiency of *C4A* in the clearance of immune complexes and apoptotic cells, whereas *C4B* is more efficient in targeting microbes (9). We found more extensive depositions of the *C4* activation product *C4b* on aggregated human IgG when adding serum from individuals carrying only the *C4A* gene as compared to serum from individuals carrying only the *C4B* gene, thus indicating that *C4A* has enhanced capability to remove immune complexes. The functional differences between *C4A* and *C4B* were also investigated in a recent study by Simoni et al (50), in which lupus-prone mice were genetically modified to express *C4* with the human *C4A/C4B*-defining amino acids. When compared to mice coding for human *C4B*, mice coding for *C4A* showed enhanced clearance of apoptotic cells, less auto-reactive B cells and lower titers of anti-SSA autoantibodies, overall supporting the notion that *C4A* has a role in prevention of autoantibody generation and autoimmunity.

In conclusion, we demonstrated a strong association between low *C4A* copy numbers and the presence of anti-SSA/SSB autoantibodies in SLE, primary SS, and myositis. Similar relationships between *C4A* copy numbers and autoantibody status were observed in all 3 diseases. Our findings suggest that anti-SSA/SSB autoantibodies are largely dependent on genetic predisposition, and this subset of autoimmune patients may be considered a specific diagnostic entity.

## ACKNOWLEDGMENTS

We thank Prof. Chack-Yung Yu for his support in the laboratory-based analysis of *C4* copy number, and Prof. David Pisetsky for critically reviewing the manuscript.

## AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Lundtoft had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study conception and design.** Lundtoft, Pucholt, Martin, Eloranta, Almlöf, Syvänen, Lindblad-Toh, Nilsson, Blom, Diaz-Gallo, Svenungsson, Rönnblom.

**Acquisition of data.** Lundtoft, Pucholt, Martin, Bianchi, Lundström, Eloranta, Sandling, Sjöwall, Jönsen, Gunnarsson, Rantapää-Dahlqvist, Bengtsson, Leonard, Baecklund, Jonsson, Hammenfors, Forsblad-d'Elia, Eriksson, Mandl, Bucher, Norheim, Johnsen, Omdal, Kvarnström, Wahren-Herlenius, Notarnicola, Andersson, Molberg, Diederichsen, Almlöf, Syvänen, Kozyrev, Lindblad-Toh, Blom, Lundberg, Nordmark, Diaz-Gallo, Svenungsson, Rönnblom.

**Analysis and interpretation of data.** Lundtoft, Pucholt, Martin, Bianchi, Lundström, Blom, Diaz-Gallo, Svenungsson, Rönnblom.

## ADDITIONAL DISCLOSURES

Author Pucholt is currently an employee of Olink Proteomics, but was employed by Uppsala University during the time the study was conducted. Author Mandl is an employee of Novartis.

## REFERENCES

- Bentham J, Morris DL, Graham DS, Pinder CL, Tombleson P, Behrens TW, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. *Nat Genet* 2015;47:1457.
- Langefeld CD, Ainsworth HC, Graham DS, Kelly JA, Comeau ME, Marion MC, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. *Nat Commun* 2017;8:16021.
- Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. *Nat Genet* 2013;45:1284.
- Taylor KE, Wong Q, Levine DM, McHugh C, Laurie C, Doherty K, et al. Genome-wide association analysis reveals genetic heterogeneity of Sjögren's syndrome according to ancestry. *Arthritis Rheumatol* 2017;69:1294–305.
- Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, Rider LG, et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. *Genes Immun* 2015;16:470–80.

6. Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. *Ann Rheum Dis* 2016;75:1558.
7. Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. *Ann Rheum Dis* 2014;73:1601.
8. Thurman JM, Yapa R. Complement therapeutics in autoimmune disease [review]. *Front Immunol* 2019;10:672.
9. Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease [review]. *Nat Rev Rheumatol* 2012;8:458.
10. Lintner KE, Wu YL, Yang Y, Spencer CH, Hauptmann G, Hebert LA, et al. Early components of the complement classical activation pathway in human systemic autoimmune diseases [review]. *Front Immunol* 2016;7:36.
11. Truedsson L. Classical pathway deficiencies—a short analytical review. *Mol Immunol*. 2015;68:14–9.
12. Birmingham DJ, Irshaid F, Nagaraja HN, Zou X, Tsao BP, Wu H, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. *Lupus* 2010;19:1272–80.
13. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol* 2002;29:288.
14. Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B, et al. Gene copy-number variation and associated polymorphisms of complement component c4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor and high copy number is a protective factor against SLE susceptibility in European Americans. *Am J Hum Genet* 2007;80:1037–54.
15. Law SK, Dodds AW, Porter RR. A comparison of the properties of two classes, C4A and C4B, of the human complement component C4. *EMBO J* 1984;3:1819–23.
16. Isenman DE, Young JR. The molecular basis for the difference in immune hemolysis activity of the Chido and Rodgers isotypes of human complement component C4. *J Immunol* 1984;132:3019.
17. Yu CY, Belt KT, Giles CM, Campbell RD, Porter RR. Structural basis of the polymorphism of human complement components C4A and C4B: gene size, reactivity and antigenicity. *EMBO J* 1986;5:2873–81.
18. Lintner KE, Patwardhan A, Rider LG, Abdul-Aziz R, Wu YL, Lundström E, et al. Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. *Ann Rheum Dis* 2016;75:1599.
19. Jüptner M, Flachsbart F, Caliebe A, Lieb W, Schreiber S, Zeuner R, et al. Low copy numbers of complement C4 and homozygous deficiency of C4A may predispose to severe disease and earlier disease onset in patients with systemic lupus erythematosus. *Lupus* 2018;27:600–9.
20. Savelli SL, Roubey RA, Kitzmiller KJ, Zhou D, Nagaraja HN, Mulvihill E, et al. Opposite profiles of complement in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) among patients with antiphospholipid antibodies (aPL). *Front Immunol* 2019;10:885.
21. Boteva L, Morris DL, Cortés-Hernández J, Martin J, Vyse TJ, Fernando MM. Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations. *Am J Hum Genet* 2012;90:445–56.
22. Kamitaki N, Sekar A, Handsaker RE, de Rivera H, Tooley K, Morris DL, et al. Complement genes contribute sex-biased vulnerability in diverse disorders. *Nature* 2020;582:577–81.
23. Sandling JK, Pucholt P, Rosenberg LH, Farias FH, Kozyrev SV, Eloranta ML, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. *Ann Rheum Dis* 2021;80:109–17.
24. Thorlacius GE, Hultin-Rosenberg L, Sandling JK, Bianchi M, Imgenberg-Kreuz J, Pucholt P, et al. Genetic and clinical basis for two distinct subtypes of primary Sjögren's syndrome. *Rheumatology (Oxford)* 2021;60:837–48.
25. Bianchi M, Kozyrev SV, Notarnicola A, Rosenberg LH, Karlsson Å, Pucholt P, et al. Contribution of rare genetic variation to disease susceptibility in a large Scandinavian myositis cohort. *Arthritis Rheumatol* 2022;74:342–52.
26. Almlöf JC, Nystedt S, Leonard D, Eloranta ML, Grosso G, Sjöwall C, et al. Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. *Hum Genet* 2019;138:141–50.
27. Eriksson D, Bianchi M, Landegren N, Nordin J, Dalin F, Mathioudaki A, et al. Extended exome sequencing identifies BACH2 as a novel major risk locus for Addison's disease. *J Intern Med* 2016;280:595–608.
28. Dangel AW, Mendoza AR, Menachery CD, Baker BJ, Daniel CM, Carroll MC, et al. The dichotomous size variation of human complement C4 genes is mediated by a novel family of endogenous retroviruses, which also establishes species-specific genomic patterns among Old World primates. *Immunogenetics* 1994;40:425–36.
29. Xie C, Yeo ZX, Wong M, Piper J, Long T, Kirkness EF, et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. *Proc Natl Acad Sci* 2017;114:8059.
30. Wu YL, Savelli SL, Yang Y, Zhou B, Rovin BH, Birmingham DJ, et al. Sensitive and specific real-time polymerase chain reaction assays to accurately determine copy number variations (CNVs) of human complement C4A, C4B, C4-long, C4-short, and RCCX modules: elucidation of C4 CNVs in 50 consanguineous subjects with defined HLA genotypes. *J Immunol* 2007;179:3012.
31. Wu Y, Lundström E, Liu CC, Yang Y, Gunnarsson I, Svenungsson E, et al. Low copy-number of complement C4A, the presence of HLA-DR3, and the presence of HLA-DR2 are independent and additive risk factors for human systemic lupus erythematosus (SLE). *J Immunol* 2010;184 Suppl:93.
32. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. *Nature* 2016;530:177–83.
33. Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz MB, et al. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. *J Autoimmun* 2020;106:102340.
34. Svenungsson E, Gustafsson JT, Grosso G, Rossides M, Gunnarsson I, Jensen-Urstad K, et al. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. *Rheumatology (Oxford)* 2020;59:3264–74.
35. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2018. URL: <https://www.R-project.org/>.
36. Routsias JG, Tzioufas AG. B-cell epitopes of the intracellular autoantigens Ro/SSA and La/SSB: tools to study the regulation of the autoimmune response. *J Autoimmun* 2010;35:256–64.
37. Yang Y, Chung EK, Zhou B, Blanchong CA, Yu CY, Füst G, et al. Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index. *J Immunol* 2003;171:2734.
38. Barba G, Rittner C, Schneider PM. Genetic basis of human complement C4A deficiency. Detection of a point mutation leading to non-expression. *J Clin Invest* 1993;91:1681–6.
39. Lokki ML, Circolo A, Ahokas P, Rupert KL, Yu CY, Colten HR. Deficiency of human complement protein C4 due to identical frame-shift mutations in the C4A and C4B genes. *J Immunol* 1999;162:3687.
40. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical

- onset of systemic lupus erythematosus. *N Engl J Med* 2003;349:1526–33.
41. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. *Arthritis Res Ther* 2011;13:R30.
  42. Theander E, Jonsson R, Sjöström B, Brokstad K, Olsson P, Henriksson G. Prediction of Sjögren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. *Arthritis Rheumatol* 2015;67:2427–36.
  43. Jonsson R, Theander E, Sjöström B, Brokstad K, Henriksson G. Autoantibodies present before symptom onset in primary Sjögren syndrome. *JAMA* 2013;310:1854–5.
  44. Ruacho G, Kvarnström M, Zickert A, Oke V, Rönnelid J, Eketjäll S, et al. Sjögren syndrome in systemic lupus erythematosus: a subset characterized by a systemic inflammatory state. *J Rheumatol* 2020;47:865.
  45. Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charon D, et al. In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. *Arthritis Rheum* 2003;48:2240–5.
  46. Morris DL, Fernando MM, Taylor KE, Chung SA, Nititham J, Alarcón-Riquelme ME, et al. MHC associations with clinical and autoantibody manifestations in European SLE. *Gene Immun* 2014;15:210.
  47. Diaz-Gallo LM, Oke V, Lundström E, Elvin K, Wu YL, Eketjäll S, et al. Four systemic lupus erythematosus subgroups, defined by autoantibodies status, differ regarding HLA-DRB1 genotype associations and immunological and clinical manifestations. *ACR Open Rheumatol* 2022;4:27–39.
  48. Chen JY, Wu YL, Mok MY, Wu YJ, Lintner KE, Wang CM, et al. Effects of complement C4 gene copy number variations, size dichotomy, and C4A deficiency on genetic risk and clinical presentation of systemic lupus erythematosus in East Asian populations. *Arthritis Rheumatol* 2016;68:1442–53.
  49. Tsang-A-Sjoe MW, Bultink IE, Korswagen LA, van der Horst A, Rensink I, de Boer M, et al. Comprehensive approach to study complement C4 in systemic lupus erythematosus: gene polymorphisms, protein levels and functional activity. *Mol Immunol* 2017;92:125–31.
  50. Simoni L, Presumey J, van der Poel CE, Castrillon C, Chang SE, Utz PJ, et al. Complement C4A regulates autoreactive B cells in murine lupus. *Cell Rep* 2020;33:108330.